- Home
- CIFR vs NVCR Comparison
CIFR vs NVCR Comparison
Compare CIFR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- NVCR
- Stock Information
- Founded
- CIFR 2021
- NVCR 2000
- Country
- CIFR United States
- NVCR Switzerland
- Employees
- CIFR N/A
- NVCR N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- NVCR Medical/Dental Instruments
- Sector
- CIFR Finance
- NVCR Health Care
- Exchange
- CIFR Nasdaq
- NVCR Nasdaq
- Market Cap
- CIFR 1.9B
- NVCR 1.9B
- IPO Year
- CIFR N/A
- NVCR 2015
- Fundamental
- Price
- CIFR $2.37
- NVCR $15.58
- Analyst Decision
- CIFR Strong Buy
- NVCR Buy
- Analyst Count
- CIFR 10
- NVCR 6
- Target Price
- CIFR $8.14
- NVCR $34.17
- AVG Volume (30 Days)
- CIFR 11.4M
- NVCR 736.7K
- Earning Date
- CIFR 05-06-2025
- NVCR 04-24-2025
- Dividend Yield
- CIFR N/A
- NVCR N/A
- EPS Growth
- CIFR N/A
- NVCR N/A
- EPS
- CIFR N/A
- NVCR N/A
- Revenue
- CIFR $151,270,000.00
- NVCR $605,220,000.00
- Revenue This Year
- CIFR $111.15
- NVCR $3.14
- Revenue Next Year
- CIFR $80.27
- NVCR $10.63
- P/E Ratio
- CIFR N/A
- NVCR N/A
- Revenue Growth
- CIFR 19.26
- NVCR 18.82
- 52 Week Low
- CIFR $1.86
- NVCR $11.70
- 52 Week High
- CIFR $7.99
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- CIFR 41.06
- NVCR 34.24
- Support Level
- CIFR $2.20
- NVCR $15.49
- Resistance Level
- CIFR $2.54
- NVCR $17.06
- Average True Range (ATR)
- CIFR 0.28
- NVCR 1.06
- MACD
- CIFR 0.08
- NVCR -0.01
- Stochastic Oscillator
- CIFR 64.56
- NVCR 20.42
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.